Zobrazeno 1 - 10
of 2 786
pro vyhledávání: ''
Autor:
Adrie Bekker, Isabelle Andrieux-Meyer, Mukesh Kumar, Helena Rabie, Marisa Groenewald, Petite Study Team, James Nielsen, Edmund V. Capparelli, Tim R. Cressey, Nicolas Salvadori, Marc Lallemant, Samantha du Toit, Ratchada Cressey, Kanchana Than-in-at, Mark F. Cotton
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 89:324-331
Antiretroviral options for neonates (younger than 28 days) should be expanded. We evaluated the pharmacokinetics, safety, and acceptability of the "4-in-1" fixed-dose pediatric granule formulation of abacavir/lamivudine/lopinavir/ritonavir (30/15/40/
Publikováno v:
World Journal of Gastroenterology
Hepatitis B virus (HBV) infection is one of the main causes of morbidity and mortality worldwide. Most children acquire the infection perinatally or during early childhood and develop a chronic hepatitis characterized by a high viral replication and
Autor:
Martin Gartland, Juan Sierra Madero, Andrea Antinori, Brian Wynne, Jean van Wyk, Pedro Cahn, Keith A. Pappa, Choy Y. Man, Pierre-Marie Girard, Mark R. Underwood, Daisy J. Brandon, Lloyd Curtis, Roberto Ortiz, Jose R. Arribas, Chien-Ching Hung, Jürgen K. Rockstroh, Michael Aboud, Jörg Sievers, Amanda Clarke, Rimgaile Urbaityte, Kimberly Y. Smith
Publikováno v:
AIDS (London, England)
To assess efficacy and safety of dolutegravir (DTG) + lamivudine (3TC) vs. DTG + tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naive adults with HIV-1 in the prespecified 144-week secondary analyses of GEMINI-1 and GEMINI-2.Desig
Autor:
Aurélien Emmanuel Martinez, Martin Siegemund, Emmanuelle Landmann, Catia Marzolini, Anne Leuppi-Taegtmeyer, Michael Dickenmann, Manuel Battegay, Nadine Cueni, Alexa Hollinger
Publikováno v:
AIDS Research and Therapy, Vol 18, Iss 1, Pp 1-5 (2021)
AIDS Research and Therapy
AIDS Research and Therapy
Background We report a case of sudden, lethal metabolic acidosis in a 70-year-old man on long-term nucleoside reverse transcriptase inhibitor (NRTI) -based antiretroviral therapy (ART) who had developed atypical necrotizing fasciitis 1 month after ki
Autor:
Theo Heller, Mary Walter, T. Jake Liang, Regina Umarova, Michele M. Tana, Gavin Cloherty, Nancy Fryzek, Xiongce Zhao, Marc G. Ghany, Naveen Gara, Sungyoung Auh, Meera Kattapuram, Edward Doo, Lauren Sullivan
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 5, Iss 11, Pp 1888-1900 (2021)
Hepatology Communications, Vol 5, Iss 11, Pp 1888-1900 (2021)
Nucleoside analogue (NA) therapy for chronic hepatitis B (CHB) is associated with improved clinical outcomes, but usually requires long‐term use. Whether treatment can be safely withdrawn and the factors associated with post‐withdrawal outcome ar
Autor:
Fabbiani, M., Rossetti, B., Ciccullo, A., Oreni, L., Lagi, F., Celani, L., Colafigli, M., De Vito, A., Mazzitelli, M., Dusina, A., Durante, M., Montagnani, F., Rusconi, S., Capetti, A., Sterrantino, G., D'Ettorre, G., Di Giambenedetto, S., Zanelli, G., Baldin, G., Borghetti, A., Latini, A., Mastroianni, C., Borghi, V., Mussini, C., Cossu, M. V., Giacomelli, A., Formenti, T., Trecarichi, E. M., Torti, C., Madeddu, G., Vecchiet, J., Vignale, F., Giacometti, A.
Publikováno v:
HIV Medicine. 22:843-853
The aim of the present study was to compare the efficacy and durability of treatment switch to two-drug (2DR) vs. three-drug (3DR) integrase inhibitor (InSTI)-based regimens in a real-life setting.Within the ODOACRE cohort, we selected adult patients
Publikováno v:
Clinical Pharmacology in Drug Development
Pharmacokinetics, safety, and tolerability of abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg were assessed in this phase 1, single‐arm, open‐label, single‐dose study in fasted healthy male (n = 4) and female (n = 8) participants of Japane
Autor:
Stefan Scholten, Jesús Santos, Jean A van Wyk, Mounir Ait-Khaled, Don Smith, Maria-Claudia Nascimento, Allan R Tenorio, Faiza Ajana, Jonathan Wright, Michael Wohlfeiler, Bryn Jones, Brian Wynne
Publikováno v:
Journal of Acquired Immune Deficiency Syndromes (1999)
Supplemental Digital Content is Available in the Text.
Background: In TANGO, switching to dolutegravir/lamivudine was noninferior at 48 weeks to continuing 3-/4-drug tenofovir alafenamide–based regimens in virologically suppressed individuals
Background: In TANGO, switching to dolutegravir/lamivudine was noninferior at 48 weeks to continuing 3-/4-drug tenofovir alafenamide–based regimens in virologically suppressed individuals
Autor:
Gong-Ying Chen, Jing Liu, Yu-Ting Zhang, Yin-Fei Hu, Li Lin, Hua-Jun Cheng, Xiao-Ben Pan, Yi-Dan Gao
Publikováno v:
World Journal of Clinical Cases
Background How to treat infantile hepatitis B virus (HBV) infection remains a controversial issue. The nucleoside analogue lamivudine (LAM) has been approved to treat children (2 to 17 years old) with chronic hepatitis B. Here, we aimed to investigat
Autor:
Yoko Inaguma, Eiichi Ohtsuka, Yukiyoshi Moriuchi, Kazuho Miyashita, Masashi Mizokami, Nobuhiko Yamauchi, Tadahiko Igarashi, Koji Izutsu, Hiroshi Gomyo, Nobuko Kubota, Ryuzo Ueda, Mio Kurata, Yoshiko Inoue, Yoshiko Atsuta, Rika Sakai, Norifumi Tsukamoto, Yoko Ushijima, Kisato Nosaka, Dai Maruyama, Sachiko Suzuki, Toshiki Uchida, Shinichiro Yoshida, Ilseung Choi, Shigeru Kusumoto, Go Yamamoto, Yasuhito Tanaka, Kensuke Kojima, Satoshi Ichikawa, Hideki Tsujimura
Publikováno v:
Cancer Science
We conducted a nationwide retrospective analysis of 116 hepatitis B virus (HBV) surface antigen (HBsAg)‐positive patients with diffuse large B‐cell lymphoma (DLBCL) and 278 HBsAg‐negative patients with DLBCL, as a control cohort, who received r